Anticoagulants Improve Survival Rates in Patients With COVID-19

June 1, 2020

Researchers from the Mount Sinai COVID Informatics Center report improved survival rates in COVID patients treated with anticoagulants.

An article published on our sister website Practical Cardiology reported on results from a new study that found improved survival rates in patients with coronavirus disease 2019 (COVID-19) treated with anticoagulants.

According to the study, which was led by researchers from the Mount Sinai COVID Informatics Center, hospitalized patients with COVID-19 had improved outcomes both in and out of the intensive care unit setting, without a significant difference in bleeding.

The research was published in the Journal of the American College of Cardiology. Previous studies have shown that COVID positive patients frequently develop life-threatening blood clots, leading to potentially deadly thromboembolic events, and they authors say their findings could provide new insight on how to treat and manage coronavirus patients in the hospital.

"This research demonstrates anticoagulants taken orally, subcutaneously, or intravenously may play a major role in caring for COVID-19 patients, and these may prevent possible deadly events associated with coronavirus, including heart attack, stroke, and pulmonary embolism," said senior corresponding author Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital in a statement. "Using anticoagulants should be considered when patients get admitted to the ER and have tested positive for COVID-19 to possibly improve outcomes.”

Read the full article on Practical Cardiology.